After completing his residency and fellowship at Children’s Hospital Los Angeles, Dr. Robison completed an additional fellowship in Pediatric Neuro-Oncology at the Dana-Farber / Children’s Hospital Cancer Center in Boston. He served as clinical instructor at Harvard Medical School and attending staff in the Pediatric Neuro-Oncology Program at Dana Farber Cancer Institute and Boston Children’s Hospital from 2010 to 2013.
In April 2013 he joined the faculty of the University of Southern California Keck School of Medicine as assistant professor of pediatrics, and now serves as attending staff in the Pediatric Neuro-Oncology Program at Children's Hospital Los Angeles.
Dr. Robison's primary research focus is developing clinical trials that test new strategies in the treatment of children with brain tumors. Specific areas of interest include molecular targeted treatment of low-grade glioma, diffuse pontine glioma, and medulloblastoma; novel treatments targeting the tumor microenvironment, including antiangiogenic and immunomodulatory strategies; and neurofibromatosis.
Novel GOPC(FIG)-ROS1 fusion in a pediatric high-grade glioma survivor. J Neurosurg Pediatr. 2017 Apr 07; 1-5. View in: PubMed
Molecular subgroups of medulloblastoma identification using noninvasive magnetic resonance spectroscopy. Neuro Oncol. 2016 Jan; 18(1):126-31. View in: PubMed
Allergic reactions and antiasparaginase antibodies in children with high-risk acute lymphoblastic leukemia: A children's oncology group report. Cancer. 2015 Dec 1; 121(23):4205-11. View in: PubMed
Tumor-Associated Macrophages in SHH Subgroup of Medulloblastomas. Clin Cancer Res. 2015 Mar 15; 21(6):1457-65. View in: PubMed
Diffuse intrinsic pontine glioma: a reassessment. J Neurooncol. 2014 Aug; 119(1):7-15. View in: PubMed
Long-term outcome of 4,040 children diagnosed with pediatric low-grade gliomas: An analysis of the Surveillance Epidemiology and End Results (SEER) database. Pediatr Blood Cancer. 2014 Jul; 61(7):1173-9. View in: PubMed
A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer. Pediatr Blood Cancer. 2014 Apr; 61(4):636-42. View in: PubMed
PID1 (NYGGF4), a New Growth-Inhibitory Gene in Embryonal Brain Tumors and Gliomas. Clin Cancer Res. 2014 Feb 15; 20(4):827-36. View in: PubMed
Medulloblastoma expresses CD1d and can be targeted for immunotherapy with NKT cells. Clin Immunol. 2013 Oct; 149(1):55-64. View in: PubMed
Predictors of neoplastic disease in children with isolated pituitary stalk thickening. Pediatr Blood Cancer. 2013 Oct; 60(10):1630-5. View in: PubMed
Morning glory disc anomaly in association with ipsilateral optic nerve glioma. Arch Ophthalmol. 2012 Aug; 130(8):1082-3. View in: PubMed
Identification of novel biologic targets in the treatment of newly diagnosed diffuse intrinsic pontine glioma. Am Soc Clin Oncol Educ Book. 2012; 625-8. View in: PubMed
Diffuse central neurocytoma with craniospinal dissemination. J Clin Neurosci. 2012 Jan; 19(1):163-6. View in: PubMed
Cerebral sinus thrombosis in a child with active ulcerative colitis and factor V Leiden. Pediatr Blood Cancer. 2009 Jul; 52(7):867-9. View in: PubMed
Incidence of adverse reactions to post-induction asparaginase (ASP) therapy in children and adolescents with high-risk acute lymphoblastic leukemia (ALL): A report from the Children's Oncology Group Study CCG-1961. J Clin Oncol. 2008 May 20; 26(15_suppl):10021. View in: PubMed
Causes of nursery death beyond the neonatal period. J Perinatol. 2003 Mar; 23(2):142-7. View in: PubMed